Objective To investigate the influence factors of non-responsiveness and lowresponsiveness to hepatitis B vaccine of infants born to hepatitis 1 surface antigen (HBsAg) positive mothers.Methods A total of 219 HBsAg positive mothers and their full-term neonates were selected from July 2011 to December 2012 in the Third People's Hospital of Taiyuan.Serologic hepatitis B virus (HBV) markers and HBV DNA load of mothers and their neonates were determined.Neonates were followed up for 12 months to observe the effect of HBV intrauterine infection,hepatitis B e antigen (HBeAg) status,sex,delivery mode,feeding option and suffering from infectious disease during followup period on the immune response to hepatitis B vaccine.Chi-square test was used in univariate analyses and unconditional Logistical regression was used in multivariate analyses.Results There were 16 cases of non-responsiveness and 33 cases of low-responsiveness in all 219 neonates.The rate of non-responsiveness and low-responsiveness was 22.37 ％.In univariate analyses,neonatal HBeAg positivity (x2 =4.895,P=0.027),natural birth (x2 =5.210,P=0.022),suffering from infectious diseases during follow-up period (x2 =4.329,P=0.037) were significantly associated with non-responsiveness and low-responsiveness.There was no relationship between mother HBeAg positivity and the level of response to hepatitis B vaccine.In multivariate analyses,natural birth (OR=2.022,95 ％CI:1.045-3.914) and suffering from infectious diseases (OR=2.324,95 ％ CI:1.058-5.103) were associated with non-responsiveness and low-responsiveness.Conclusion Infants born to HBsAg positive mothers with natural birth or suffering from infectious diseases during follow-up period are more likely to be non-responsiveness and lowresponsiveness to hepatitis B vaccine.

Radiation therapy (RT) is one of main methods of comprehensive treatment of esophageal cancer (EC). It plays a dual role in the immune system and can activate systemic immune response. However, the effect of tumor cytotoxicity induced by RT is limited, and it can induce abscopal effect in combination with immunotherapy (IT). A number of clinical studies have shown the effect and great potential of immune checkpoint inhibitors (ICIs), such as PD-1/L1 antibodies in advanced EC. Besides, RT and ICIs exert a synergistic effect. Currently, multiple ongoing studies related to concurrent radiochemotherapy combined with IT is expected to determine the efficacy of this comprehensive treatment in EC and elucidate the efficiency and cost-effectiveness.

Objective:To summarize survival outcomes and prognostic factors in esophageal cancer (EC) patients treated with intensity-modulated radiotherapy (IMRT).Methods:A retrospective analysis was performed on the clinical and follow-up data of 1 637 patients with EC who were admitted to our hospital from January 2005 to December 2017 and met the inclusion criteria.The 5-year overall survival (OS), progression-free survival (PFS) and pattern of recurrence were analyzed. The Kaplan-Meier method was used to calculate survival rates, Log-rank test for univariate analysis and Cox method for multivariate analysis were used to detect survival difference.Results:1-year, 3-year and 5-year OS and PFS of the entire group were 65.9% and 45.8%, 34.2% and 25.0%, 27.0% and 18.5%, respectively. Median OS and PFS were 19.4 months (95% CI=18.0-20.7 months) and 10.4 months (95% CI=9.3-11.3 months), respectively. Univariate analysis showed that the sex, KPS, tumor location, T stage, N stage, M stage, TNM stage, radiation dose and treatment modality were prognostic factors for 5-year OS and PFS of EC patients ( P<0.05). Multivariate analysis indicated that the sex, KPS, TNM stage, radiation dose and treatment modality were independent prognostic factors for 5-year OS and PFS ( P<0.05). Conclusions:EC patients treated with IMRT can obtain a promising survival. The sex, KPS, TNM stage, radiation dose and treatment modality are independent prognostic factors for prognosis.